Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ETA receptor selective antagonists using FRET assay

https://doi.org/10.1016/j.bmcl.2017.04.049Get rights and content

Abstract

The endothelin axis and in particular the two receptor subtypes, ETA and ETB, are under investigation for the treatment of various diseases such as pulmonary arterial hypertension, fibrosis, renal failure and cancer. Previous work in our lab has shown that 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives exhibit noteworthy endothelin receptor antagonist activity. A series of analogues with modifications centered around position 6 of the heterocyclic quinolone core and replacement of the aryl carboxylic acid group with an isosteric tetrazole ring was designed and synthesized to further optimize the structure activity relationship. The endothelin receptor antagonist activity was determined by in vitro Förster resonance energy transfer (FRET) using GeneBLAzer® assay technology. The most potent member of this series exhibited ETA receptor antagonist activity in the subnanomolar range with an IC50 value of 0.8 nM, and was 1000-fold selective for the ETA receptor compared to the ETB receptor. Its activity and selectivity profile resembles that of the most recently approved drug, macitentan.

Section snippets

Acknowledgments

The authors thank Dr. Vladimir Poltoratsky and Zhihui Xiao for their help with the in vitro FRET assay. Support for this research was provided by Saint John’s University.

References (27)

  • T. Masaki

    Trends Pharmacol Sci

    (2004)
  • C. Boss et al.

    Bioorganic Med Chem Lett

    (2016)
  • H.J. Patel et al.

    Bioorg Med Chem Lett

    (2010)
  • A.P. Davenport et al.

    Pharmacol Rev

    (2016)
  • J.-D. Aubert et al.

    J Med Chem

    (2016)
  • J.J. Maguire et al.

    Br J Pharmacol

    (2014)
  • G.M. Keating

    Am J Cardiovasc Drugs

    (2016)
  • I.S. Hong et al.

    Ann Pharmacother

    (2014)
  • A. Bagnato et al.

    Endocr Relat Cancer

    (2005)
  • J.-D. Aubert et al.

    Expert Opin Ther Targets

    (2009)
  • J. Nelson et al.

    Nat Rev

    (2003)
  • L. Rosano et al.

    Nat Rev

    (2013)
  • K. Kitada et al.

    Cardiol Res Pract

    (2012)

    • Cited by (4)

    • Tetrazole hybrids with potential anticancer activity

      2019, European Journal of Medicinal Chemistry
      Citation Excerpt :

      The conjugate 17b possessed broad anticancer activity agaist all tested human cancer cell lines with growth inhibitory of 17.18%–97.56% at 10 nM, suggesting that it could act as a platform for further investigations. A series of ciprofloxacin-tetrazoles 19 and pipemidic acid-tetrazoles 20 (Fig. 5) were tested for their in vitro anti-proliferative activity against cervix (SiHa), breast (MDAMB-231) and pancreatic carcinoma cell lines by the sulforhodamine B (SRB) assay [78–80]. Among them, 5 against SiHa cancer cell line, 11 against MDA-MB-231 and 1 against PANC-1 cancer cell lines exhibited greater inhibition on cell growth than the reference tamoxifen [80].

    • Pharmacological Significance of Triazoles and Tetrazoles in Neurodegenerative Disease: An Overview

      2022, N-Heterocycles: Synthesis and Biological Evaluation

    • Synthesis of 2-Imino-1, 2-dihydroquinolines via Copper Catalysis

      2021, Chinese Journal of Organic Chemistry

    • Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity

      2019, Journal of Medicinal Chemistry
    View full text
    © 2017 Elsevier Ltd. All rights reserved.